高使用低成本他汀类药物是否与二级预防中胆固醇质量标志物的改善较差相关？
Does higher usage of low-cost statins correlate with a poorer achievement in cholesterol quality markers for secondary prevention?
机构信息
North Curry Health Centre, Greenway, North Curry, Taunton, Somerset, UK.
出版信息
Br J Gen Pract. 2010 Jan;60(570):50-2. doi: 10.3399/bjgp10X482112.
Abstract
There is pressure on primary care trusts, and therefore on GPs, to reach specific levels of use of low-cost statins as a proportion of total statin prescribing. This simple study looks at some markers of the quality of the results achieved. A correlation is found between a higher proportion of low-cost statin prescribing and lower achievement raising questions as to whether financial savings may be offset by poorer results.
摘要
基层医疗信托机构（primary care trusts）面临压力，因此全科医生（general practitioners，简称 GPs）也面临压力，需要达到特定的低成本他汀类药物使用率标准，作为他汀类药物总处方的一部分。这项简单的研究着眼于实现结果质量的一些指标。研究发现，低成本他汀类药物处方的比例较高与较低的达标率之间存在相关性，这引发了人们的质疑，即节省的费用是否会因较差的结果而抵消。
相似文献
1
Does higher usage of low-cost statins correlate with a poorer achievement in cholesterol quality markers for secondary prevention?高使用低成本他汀类药物是否与二级预防中胆固醇质量标志物的改善较差相关？
Br J Gen Pract. 2010 Jan;60(570):50-2. doi: 10.3399/bjgp10X482112.
2
Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.使用诊断聚类方法进行HMG-CoA还原酶抑制剂治疗的治疗成本核算和药物监测。
Clin Ther. 1999 Jan;21(1):218-35. doi: 10.1016/S0149-2918(00)88280-6.
3
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.与阿托伐他汀、普伐他汀和辛伐他汀相比，瑞舒伐他汀在将患者低密度脂蛋白胆固醇水平降至目标值方面具有成本效益：STELLAR试验分析。
Eur J Cardiovasc Prev Rehabil. 2005 Feb;12(1):18-28.
4
Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.
Eur Heart J. 1998 Apr;19 Suppl C:C59-65.
5
Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study.他汀类药物治疗对医疗资源利用的长期影响及其在心血管疾病一级预防中的成本效益：一项基于记录链接的研究。
Eur Heart J. 2014 Feb;35(5):290-8. doi: 10.1093/eurheartj/eht232. Epub 2013 Jul 9.
6
[Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].[巴西公共医疗系统中辛伐他汀与阿托伐他汀在心血管事件二级预防中的成本效益分析]
Value Health. 2011 Jul-Aug;14(5 Suppl 1):S29-32. doi: 10.1016/j.jval.2011.05.024.
7
Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.他汀类药物用于慢性肾脏病一级心血管预防的成本效益。
J Am Coll Cardiol. 2013 Mar 26;61(12):1250-8. doi: 10.1016/j.jacc.2012.12.034.
8
A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.一种评估他汀类药物在实现英国国家服务框架目标胆固醇水平方面成本效益的模型。
Pharmacoeconomics. 2003;21 Suppl 1:1-11. doi: 10.2165/00019053-200321001-00001.
9
Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.哪种他汀类药物治疗高胆固醇血症最有效？一项成本效益分析。
Clin Ther. 1999 Nov;21(11):1924-36. doi: 10.1016/S0149-2918(00)86740-5.
10
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.一种用于实现低密度脂蛋白胆固醇目标水平的替代他汀类药物的成本效益模型。
Int J Clin Pract. 2001 May;55(4):243-9.
引用本文的文献
1
Achievement of cholesterol targets and prescribing of higher-cost statins: a cross-sectional study in general practice.实现胆固醇目标与开具高成本他汀类药物处方：一般实践中的一项横断面研究。
Br J Gen Pract. 2012 Dec;62(605):e815-20. doi: 10.3399/bjgp12X659286.
2
Generic and therapeutic substitutions in the UK: are they a good thing?英国的非专利药和通用名药替代：这是好事吗？
Br J Clin Pharmacol. 2010 Sep;70(3):335-41. doi: 10.1111/j.1365-2125.2010.03718.x.
本文引用的文献
1
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).瑞舒伐他汀与阿托伐他汀、辛伐他汀和普伐他汀不同剂量疗效及安全性的比较（STELLAR*试验）
Am J Cardiol. 2003 Jul 15;92(2):152-60. doi: 10.1016/s0002-9149(03)00530-7.
Zotero 插件